09:00 - 13:00
Country Focus Workshop
Canada, Malta, United Kingdom, Germany
& THE ROLE OF BIG PHARMA
09:00 - 09:20 | Malta's Journey
What key drivers were behind the introduction of the production of cannabis for medicinal use act.
09:20 - 09:40 | Research and Development
How has the change in law affected the scientific sector in Malta?
09:40 - 10:00 | The Future of Medical Cannabis
How will a patient-centric approach affect policy and supply chain decisions.
10:00 - 10:20 | WHO and its Impact on National Polotics
International organisations such as the World Health Organisation are becoming increasingly vocal on the application of medical cannabis. How is this impacting policy makers at state-level across different continents?
10:20 - 10:40 | Monitoring and Control
What steps are being taken towards standardisation and quality control on a European level?
10:40 - 11:00 | From Cultivation to Waste Disposal
How is Malta enforcing regulatory procedures?
11:00 - 11:20 | Intellectual Property and its Challenges
How can pharmaceutical companies develop an effective intellectual property and commercial strategy for plant-based products?
11:20 - 11:40 | Traditional Drugs
If Big Pharma doesn't get involved in the medical cannabis industry, what might the financial repercussions be?
11:40 - 12:00 | Synthetic Cannabinoids
What are the benefits and disadvantages of man-made cannabinoids?
12:00 - 12:20 | Social Trends
Medical cannabis is being championed as a natural remedy which can treat a variety of physical and psychological disorders. How might this social shift towards herbal based drugs stack up against the reputation of pharmaceutical companies?
12:20 - 12:40 | Investment and Big Pharma
There's no doubt pharmaceutical companies have the resources to research, develop and market synthetic cannabinoids. With demand exceeding supply in the market how might they use this to carve out their niche in the industry?
12:40 - 13:00 | A Long Process
Pharmaceutical companies have a notoriously long process to get a drug approved. If they move in the direction of synthetic cannabinoids how can they avoid losing out due to the long and expensive timeline?
14:00 - 18:00
Country Focus Workshop
Australia, New Zealand, Asia, LatAm, United States
& THE START-UP PITCH
14:00 - 16:00 | Start-Up Pitch
10 medical cannabis startups with the most innovative projects will pitch on stage in front of established entrepreneurs and savvy investors . Set your sights on the moon and battle it out in a shark-tank environment with some tough love from a select panel of stern judges.
16:00 - 16:20 | From ICO's to Cannabis
Following the recent pitfall that many investors have experienced with ICO's worldwide, could cannabis pave the way for more secure investment opportunities?
16:20 - 16:40 | Market Overview
What is the European medicinal cannabis market worth and what are the future projections?
16:40 - 17:00 | Funding and Research
Both the public and private sector are investing in scientific research. How can the two work together for both the benefit of patients and future commercial success?
17:00 - 17:20 | Mitigating Risk
Investment firms have highlighted several risk factors in investing in the European medical cannabis industry. How are these to be reduced?
17:20 - 17:40 | VC's and PE
Venture capitalists and private equity funds are heavily involved in the North American medical cannabis market. How does this compare to Europe?
17:40 - 18:00 | Going Public
IPO's are happening in Canada. Will the trend move to Europe?
Viking PC Health Ltd. is a company registered in Malta, having company registration number C54356 and VAT number MT20561207. Copyright Viking PC Health Ltd. All rights reserved © 2011 – 2019